<p>雅培（Abbott Laboratories，股票代码：ABT）周一宣布，加拿大卫生部已批准其可溶解支架——Esprit BTK Everolimus Eluting Resorbable Scaffold System。</p>
<p>该设备用于治疗下肢慢性威胁性缺血（CLTI）患者。它可以保持动脉通畅，并释放药物依维莫司，以支持在支架完全溶解之前的愈合。</p>
<p>超过 80 万加拿大人患有周围动脉疾病（PAD）。CLTI 是 PAD 的一种严重形式，动脉因斑块堵塞而阻碍血液和氧气流向小腿和脚部。CLTI 患者常常经历剧烈疼痛和难以愈合的开放性伤口。</p>
<p>如需评论和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

雅培

<p>雅培已获得加拿大卫生部批准其 Esprit BTK 依维莫司释放可吸收支架系统，该可溶支架旨在治疗膝下慢性肢体威胁缺血（CLTI）。该设备有助于保持动脉通畅，并释放药物依维莫司以促进愈合，直至其完全溶解，满足超过 80 万名患有外周动脉疾病（PAD）的加拿大人的需求</p>

<p>Abbott Laboratories (ABT) on Monday announced that Health Canada has approved its dissolvable stent, the Esprit BTK Everolimus Eluting Resorbable Scaffold System.</p>
<div class="lb-trans"><p>雅培（Abbott Laboratories，股票代码：ABT）周一宣布，加拿大卫生部已批准其可溶解支架——Esprit BTK Everolimus Eluting Resorbable Scaffold System。</p>
</div><p>The device is used to treat people with chronic limb threatening ischemia (CLTI) below-the-knee (BTK). It keeps arteries open and delivers the drug everolimus to support healing before the stent fully dissolves.</p>
<div class="lb-trans"><p>该设备用于治疗下肢慢性威胁性缺血（CLTI）患者。它可以保持动脉通畅，并释放药物依维莫司，以支持在支架完全溶解之前的愈合。</p>
</div><p>More than 800,000 Canadians are living with Peripheral Artery Disease (PAD). CLTI is a severe form of PAD in which arteries become clogged with plaque, blocking blood flow and oxygen to the lower leg and foot. People with CLTI often experience severe pain and non-healing open wounds.</p>
<div class="lb-trans"><p>超过 80 万加拿大人患有周围动脉疾病（PAD）。CLTI 是 PAD 的一种严重形式，动脉因斑块堵塞而阻碍血液和氧气流向小腿和脚部。CLTI 患者常常经历剧烈疼痛和难以愈合的开放性伤口。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如需评论和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

雅培的 Esprit BTK 可溶解支架已获加拿大卫生部批准